Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy

被引:3
|
作者
Lauriola, Angela [1 ]
Davalli, Pierpaola [2 ]
Marverti, Gaetano [2 ]
Santi, Spartaco [3 ,4 ]
Caporali, Andrea [5 ]
D'Arca, Domenico [2 ]
机构
[1] Univ Verona, Dept Biotechnol, I-37134 Verona, Italy
[2] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Via G Campi 287, I-41125 Modena, Italy
[3] CNR, Inst Mol Genet Luigi Luca Cavalli Sforza, I-40136 Bologna, Italy
[4] IRCCS, Ist Ortoped Rizzoli, I-40136 Bologna, Italy
[5] Univ Edinburgh, BHF Ctr Cardiovasc Sci, Edinburgh EH4 2XU, Scotland
关键词
immunotherapy; cancer; immunotherapy-challenges; immunotherapy-limitations; PROSTATE-CANCER; PHASE-II; NAB-PACLITAXEL; PATIENTS PTS; OPEN-LABEL; T-CELLS; TUMOR MICROENVIRONMENT; RECURRENT GLIOBLASTOMA; PLUS CHEMOTHERAPY; BEVACIZUMAB BEV;
D O I
10.3390/cancers15113009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy is a cancer treatment that exploits the capacity of the body's immune system to prevent, control, and remove cancer. Immunotherapy has revolutionized cancer treatment and significantly improved patient outcomes for several tumor types. However, most patients have not benefited from such therapies yet. Within the field of cancer immunotherapy, an expansion of the combination strategy that targets independent cellular pathways that can work synergistically is predicted. Here, we review some consequences of tumor cell death and increased immune system engagement in the modulation of oxidative stress and ubiquitin ligase pathways. We also indicate combinations of cancer immunotherapies and immunomodulatory targets. Additionally, we discuss imaging techniques, which are crucial for monitoring tumor responses during treatment and the immunotherapy side effects. Finally, the major outstanding questions are also presented, and directions for future research are described.
引用
收藏
页数:41
相关论文
共 50 条
  • [41] Cytokines in cancer immunity and immunotherapy
    Smyth, MJ
    Cretney, E
    Kershaw, MH
    Hayakawa, Y
    IMMUNOLOGICAL REVIEWS, 2004, 202 : 275 - 293
  • [42] IMMUNOTHERAPY FOR MELANOMA - THE NEWEST THERAPEUTIC POSSIBILITIES TARGETING CANCER IMMUNITY CYCLE AND TUMOR MICROENVIRONMENT
    Kielbik, Aleksander
    Wawryka, Piotr
    Chwilkowska, Agnieszka
    POSTEPY BIOLOGII KOMORKI, 2019, 46 (02) : 129 - 146
  • [43] Targeting cellular pathways in glioblastoma multiforme
    Pearson, Joshua R. D.
    Regad, Tarik
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2017, 2
  • [44] Targeting Rank Ligand Pathways in Combination Immunotherapy
    Ahern, Elizabeth
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 103 - 104
  • [45] Targeting multiple coinhibitory pathways for immunotherapy of melanoma
    Cai, Guifang
    Freeman, Gordon
    CANCER RESEARCH, 2009, 69
  • [46] Targeting cellular pathways in glioblastoma multiforme
    Joshua R D Pearson
    Tarik Regad
    Signal Transduction and Targeted Therapy, 2
  • [47] REPORT ON THE KEYSTONE SYMPOSIUM - CELLULAR-IMMUNITY AND THE IMMUNOTHERAPY OF CANCER-II - INTRODUCTION
    LOTZE, MT
    FINN, OJ
    JOURNAL OF IMMUNOTHERAPY, 1993, 14 (02): : 79 - 87
  • [48] Modulating cellular senescence to reinstate natural killer cell immunity for pancreatic cancer immunotherapy
    Ruscetti, Marcus
    CANCER RESEARCH, 2022, 82 (12)
  • [49] Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?
    Zuo, Shiyi
    Song, Jiaxuan
    Zhang, Jingxuan
    He, Zhonggui
    Sun, Bingjun
    Sun, Jin
    THERANOSTICS, 2021, 11 (15): : 7471 - 7487
  • [50] Targeting androgen-independent pathways: new chances for patients with prostate cancer?
    Cattrini, C.
    Zanardi, E.
    Vallome, G.
    Cavo, A.
    Cerbone, L.
    Di Meglio, A.
    Fabbroni, C.
    Latocca, M. M.
    Rizzo, F.
    Messina, C.
    Rubagotti, A.
    Barboro, P.
    Boccardo, F.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 118 : 42 - 53